SRGN ( Seragen, Inc.) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SRGN ( Seragen, Inc.)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Peckham who wrote (2)	4/10/1997 12:32:00 PM
From: Robert Harvey	of 52

John I arrived at Boston U. in 1987, right about the time the University's investment in Seragen was really making news. From its inception, it has been a controversial and money-losing endeavor championed by John Silber (retired B.U. president) and his Trustee Board buddies. Lately, however, the Company has been showing signs of taking the steps necessary to not only stay solvent, listed, and reasonably current on its bills, but is also getting closer to hearing some feedback from the FDA concerning its flagship IL-2 Fusion Protein. Any near-term movement in the stock will be dependent upon news of other partnerships created for development and funding of SRGN's other compounds. The Company definitely has promise and I have hold shares knowing that any reward may be awhile coming. But, looking at yesterday's announcement, it is encouraging to hear that Eli Lilly is taking 1,000,000 shares for the assumption of some necessary cash outlays. It shows that maybe some people see a brighter future. If anyone has a more technical assesment I would like to hear it. Bob H.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next